May 3 & 5 Workshop About Cancer Drug Dosing

[Bestbird]

If you’re concerned about the toxicity of anticancer drugs and interested in hearing more about this important topic, you may want to attend the May 3 & 5 workshop hosted by the FDA and ASCO! Speakers and panelists will discuss research and clinical challenges regarding dose optimization, and highlight strategies to improve dose optimization for anticancer agents. I’m proud to announce that MBC patient advocates Sheila McGlown and Anne Loeser of the Patient-Centered Dosing Initiative (PCDI) will be panelists!

View more information and register for either or both days of the May 3/5 workshop at: fda.gov/news-events/fda-mee...

[Hazelgreen]

Thanks so much, Anne, for posting this important workshop. I will look forward to hearing the webcast afterthe event.

[Bestbird in reply to Hazelgreen]

Hazelgreen, thank you for your kind words! This should indeed be an interesting opportunity to learn more about what's being done to reform the "more is better" oncology drug dosing paradigm!

[NPmary]

Thank you.

[Nature613]

Hi Anne,Yes. Thank you for letting us know about this. This is good stuff.

Best wishes.

[LadyKatarina]

Do you know if they are doing any new studies using lower doses of the AI's and /or fulvestrant? I have some papers but they are older. And thank you so much for all of your hard work on this topic! I can't believe you have the energy to do what you have done--so thankful. Kay

[Bestbird in reply to LadyKatarina]

LadyKatarina, I'm not aware of any new studies regarding already-approved endocrine therapies, but that doesn't mean that someone somewhere isn't addressing the issue. That said, I doubt there'll be a future study about Fulvestrant dose de-escalation because it was initially approved at 250 mg and it was subsequently found that it was more effective at 500 mg, which became the new approved dose.

[OneLump22 in reply to Bestbird]

*loud whistle* 500mg? Wow. Not sure if that's good or bad. Just sounds like a lot. To me anyway, but I'm not a medical professional. That could be nothing for all I know.

[TammyCross in reply to OneLump22]

As I understand it, that was all they could inject, and that is why they have to use both hips. The oral SERDs, one oncologist told me, are more effective because they can increase how much is delivered.

[Bestbird in reply to TammyCross]

It has to do with bioavailability.

[LadyKatarina]

Thank you so much! Best to you--Kay

[OneLump22]

Yes! So will I. I have been very concerned about some of my meds.

[TammyCross]

This looks fascinating and important -- finding new ways to discover optimal dose, not just highest tolerated dose. (I say this as I face starting on highest dose of Verzenio, and going down only if the side effects are too much for me. Seems like a dumb way to go. Why not start on the lowest dose, and work up?)

I cannot attend. Will recordings be available -- or materials that can be downloaded after the conference? I am sure people here will share important nuggets. What I really wish is that we could make our docs attend.

[Bestbird in reply to TammyCross]

Yes, recordings will be available in a few weeks.